Clinical Trials Directory

Trials / Enrolling By Invitation

Enrolling By InvitationNCT06649799

Comparative Study on Changes in Anterior Chamber Cytokines, Oxidative Stress, and Pupil Size After LenSx and Z8 Femtosecond Lasers

Status
Enrolling By Invitation
Phase
N/A
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
Sex
All
Age
50 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Femtosecond laser-assisted cataract surgery is rapidly gaining popularity. Among the 5 femtosecond laser platforms available at present for cataract surgery, the Femto LDV Z8 (Ziemer Ophthalmic Systems AG) is a high-frequency system and delivers energy pulses in nanojoule levels, while Lensx platform (Lensx, Alcon Laboratories, Inc.) used a high-energy laser system. In femtosecond laser-assisted cataract surgery, the laser pretreatment is associated with breakdown of blood-aqueous barrier (BAB) associated with increased aqueous total prostaglandin, cytokines and Oxygen-free radicals concentration. The prostaglandin rise immediately after laser pretreatment is further thought to be the causative factor for the intraoperative miosis in femtosecond laser-assisted cataract surgery. However, the analysis of anterior chamber inflammatory factors, oxidative stress, and pupil size after femtosecond laser-assisted cataract surgery between different laser platforms has not been investigated in clinical studies. Understanding the cytokine and chemokine changes related to the laser pretreatment provides better insight into the inflammatory response in femtosecond laser-assisted cataract surgery.

Conditions

Interventions

TypeNameDescription
DEVICELenSxThe patients in Group 1 conduct FLACS under LenSx
DEVICEZ8The patients in Group 1 conducted FLACS using Z8

Timeline

Start date
2024-08-01
Primary completion
2025-06-30
Completion
2025-06-30
First posted
2024-10-21
Last updated
2024-10-21

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06649799. Inclusion in this directory is not an endorsement.